Indegene Share Price Target For 2024, 2025, 2026, 2027, 2028, 2029, 2030: Indegene is a international organisation that gives superior solutions and services to the pharmaceutical, biotechnology, and healthcare sectors. As an corporation leveraging deep medical expertise, huge technology talents, and domain understanding, Indegene is poised for huge boom in the coming years. This complete assessment will provide projected share prices for Indegene from 2024 to 2030, incorporating crucial financial metrics and trends affecting the corporation’s marketplace overall performance. The key-word “Indegene share price” may be strategically dispensed within the course of this text to make certain it is seo-nice and without difficulty to be had to fascinated stakeholders.
OVERVIEW OF INDEGENE SHARE PRICE
- MARKET CAP: ₹13.67KCr
- OPEN: ₹572.00
- HIGH: ₹576.00
- LOW: ₹566.10
- P/E RATIO: 37.97
- DIVIDEND YIELD: N/A
- 52 WEEK HIGH: ₹660.00
- 52 WEEK LOW: ₹470.10
INDEGENE SHARE PRICE RECENT
Projected Indegene Share Price 2024 – 2030
The table beneath provides the projected monthly percentage expenses for Indegene from 2024 to 2030. These projections keep in mind marketplace dispositions, business enterprise performance, and financial signs.
| YEAR | SHARE PRICE TARGET |
| 2024 | ₹674.50 |
| 2025 | ₹733.20 |
| 2026 | ₹883.20 |
| 2027 | ₹990.45 |
| 2028 | ₹1089.78 |
| 2029 | ₹1192.45 |
| 2030 | ₹1278.15 |
Key Factors For Indegene Share Price:
- Innovation in virtual health and telemedicine.
- Strategic partnerships and collaborations.
- Investment in human capital and talent improvement.
- Financial Performance and Key Metrics
INVESTOR TYPE AND RATIOS FOR INDEGENE SHARE PRICE
- Retail And Others: 92.37%
- Foreign Institutions: 3.79%
- Mutual Funds: 2.31%
- Other Domestic Institutions: 1.53%
Indegene share price objectives from 2024 to 2030 illustrate its functionality for sustained boom and charge advent inside the global healthcare sector. With a sturdy cognizance on innovation, market boom, and operational excellence, Indegene is well-positioned to capitalize on growing opportunities and navigate marketplace challenges efficiently. Investors and stakeholders can don’t forget those projections and the agency’s strategic tasks whilst comparing funding possibilities in the dynamic healthcare and biotechnology industries.
